Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study

Martin Hjorth; Øyvind Hjertner; Lene Meldgaard Knudsen; Nina Gulbrandsen; Erik Holmberg; Per Trøllund Pedersen; Niels Frost Andersen; Björn Andréasson; Rolf Billström; Kristina Carlson; Margaretha S Carlsson; Max Flogegård; Karin Forsberg; Peter Gimsing; Torbjörn Karlsson; Olle Linder; Hareth Nahi; Annika Othzén; Agneta Swedin; Nordic Myeloma Study Group (NMSG)

doi:10.1111/j.1600-0609.2012.01775.x

Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study

Martin Hjorth, Øyvind Hjertner, Lene Meldgaard Knudsen, Nina Gulbrandsen, Erik Holmberg, Per Trøllund Pedersen, Niels Frost Andersen, Björn Andréasson, Rolf Billström, Kristina Carlson, Margaretha S Carlsson, Max Flogegård, Karin Forsberg, Peter Gimsing, Torbjörn Karlsson, Olle Linder, Hareth Nahi, Annika Othzén, Agneta Swedin, Nordic Myeloma Study Group (NMSG)

46 Citations (Scopus)

Abstract

Thalidomide and bortezomib have been frequently used for second-line therapy in patients with myeloma relapsing after or refractory to initial melphalan-based treatment, but no randomized trials have been published comparing these two treatment alternatives.

Original language	English
Journal	European Journal of Haematology
Volume	88
Issue number	6
Pages (from-to)	485-96
Number of pages	12
ISSN	0902-4441
DOIs	https://doi.org/10.1111/j.1600-0609.2012.01775.x
Publication status	Published - 2012

Keywords

Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Boronic Acids
Cross-Over Studies
Dexamethasone
Disease-Free Survival
Drug Resistance, Neoplasm
Female
Humans
Male
Melphalan
Middle Aged
Multiple Myeloma
Pyrazines
Quality of Life
Recurrence
Thalidomide

Access to Document

10.1111/j.1600-0609.2012.01775.x

Cite this

Hjorth, M., Hjertner, Ø., Knudsen, L. M., Gulbrandsen, N., Holmberg, E., Pedersen, P. T., Andersen, N. F., Andréasson, B., Billström, R., Carlson, K., Carlsson, M. S., Flogegård, M., Forsberg, K., Gimsing, P., Karlsson, T., Linder, O., Nahi, H., Othzén, A., Swedin, A., & Nordic Myeloma Study Group (NMSG) (2012). Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study. European Journal of Haematology, 88(6), 485-96. https://doi.org/10.1111/j.1600-0609.2012.01775.x

Hjorth, M, Hjertner, Ø, Knudsen, LM, Gulbrandsen, N, Holmberg, E, Pedersen, PT, Andersen, NF, Andréasson, B, Billström, R, Carlson, K, Carlsson, MS, Flogegård, M, Forsberg, K, Gimsing, P, Karlsson, T, Linder, O, Nahi, H, Othzén, A, Swedin, A & Nordic Myeloma Study Group (NMSG) 2012, 'Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study', European Journal of Haematology, vol. 88, no. 6, pp. 485-96. https://doi.org/10.1111/j.1600-0609.2012.01775.x

@article{0888a0f28f414438a8494b1b751ad797,

title = "Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study",

abstract = "Thalidomide and bortezomib have been frequently used for second-line therapy in patients with myeloma relapsing after or refractory to initial melphalan-based treatment, but no randomized trials have been published comparing these two treatment alternatives.",

keywords = "Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Boronic Acids, Cross-Over Studies, Dexamethasone, Disease-Free Survival, Drug Resistance, Neoplasm, Female, Humans, Male, Melphalan, Middle Aged, Multiple Myeloma, Pyrazines, Quality of Life, Recurrence, Thalidomide",

author = "Martin Hjorth and {\O}yvind Hjertner and Knudsen, \{Lene Meldgaard\} and Nina Gulbrandsen and Erik Holmberg and Pedersen, \{Per Tr{\o}llund\} and Andersen, \{Niels Frost\} and Bj{\"o}rn Andr{\'e}asson and Rolf Billstr{\"o}m and Kristina Carlson and Carlsson, \{Margaretha S\} and Max Flogeg{\aa}rd and Karin Forsberg and Peter Gimsing and Torbj{\"o}rn Karlsson and Olle Linder and Hareth Nahi and Annika Othz{\'e}n and Agneta Swedin and \{Nordic Myeloma Study Group (NMSG)\}",

note = "{\textcopyright} 2012 John Wiley \& Sons A/S.",

year = "2012",

doi = "10.1111/j.1600-0609.2012.01775.x",

language = "English",

volume = "88",

pages = "485--96",

journal = "European Journal of Haematology",

issn = "0902-4441",

publisher = "John Wiley and Sons Inc.",

number = "6",

}

TY - JOUR

T1 - Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma

T2 - a randomized study

AU - Hjorth, Martin

AU - Hjertner, Øyvind

AU - Knudsen, Lene Meldgaard

AU - Gulbrandsen, Nina

AU - Holmberg, Erik

AU - Pedersen, Per Trøllund

AU - Andersen, Niels Frost

AU - Andréasson, Björn

AU - Billström, Rolf

AU - Carlson, Kristina

AU - Carlsson, Margaretha S

AU - Flogegård, Max

AU - Forsberg, Karin

AU - Gimsing, Peter

AU - Karlsson, Torbjörn

AU - Linder, Olle

AU - Nahi, Hareth

AU - Othzén, Annika

AU - Swedin, Agneta

AU - Nordic Myeloma Study Group (NMSG)

PY - 2012

Y1 - 2012

N2 - Thalidomide and bortezomib have been frequently used for second-line therapy in patients with myeloma relapsing after or refractory to initial melphalan-based treatment, but no randomized trials have been published comparing these two treatment alternatives.

AB - Thalidomide and bortezomib have been frequently used for second-line therapy in patients with myeloma relapsing after or refractory to initial melphalan-based treatment, but no randomized trials have been published comparing these two treatment alternatives.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Boronic Acids

KW - Cross-Over Studies

KW - Dexamethasone

KW - Disease-Free Survival

KW - Drug Resistance, Neoplasm

KW - Female

KW - Humans

KW - Male

KW - Melphalan

KW - Middle Aged

KW - Multiple Myeloma

KW - Pyrazines

KW - Quality of Life

KW - Recurrence

KW - Thalidomide

UR - https://www.scopus.com/pages/publications/84861198392

U2 - 10.1111/j.1600-0609.2012.01775.x

DO - 10.1111/j.1600-0609.2012.01775.x

M3 - Journal article

C2 - 22404182

SN - 0902-4441

VL - 88

SP - 485

EP - 496

JO - European Journal of Haematology

JF - European Journal of Haematology

IS - 6

ER -

Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this